Business
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Upda...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Eupraxia common shares now listed on the Nasdaq Capital Market (\"Nasdaq\") under the symbol \"EPRX\"\n \n \n Additional data from RESOLVE study evaluating EP-104GI for the treatment of eosinophilic esophagitis (\"EoE\") expected in the second quarter of 2024\n \n \n Annual general and special meeting scheduled for\n \n June 6, 2024\n \n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n May 8, 2024\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quarter of 2024 and provided a corporate update.\n \n \n \"The first quarter of 2024 was a highly productive period for Eupraxia, with our team achieving multiple clinical and corporate milestones,\" said Dr.\n \n James Helliwell\n \n , CEO of Eupraxia. \"We now possess a stronger balance sheet, a NASDAQ listing providing greater access to U.S. investors, a Phase 3 ready asset and a Phase 2a asset advancing in the clinic. Looking forward to the remainder of 2024, we anticipate regular data updates from our RESOLVE study as well as anticipated U.S. Food and Drug Administration feedback on the registration path for EP-104GI. In addition, we're continuing business development discussions with prospective strategic partners for our Phase 3 osteoarthritis program and look forward to expanding our funding opportunities for its continued development.\"\n \n \n \n \n Recent Operational and Financial Highlights\n \n \n \n \n \n Subsequent to quarter end, on\n \n April 20, 2024\n \n , the Company presented two abstracts at the Osteoarthritis Research Society International (\"OARSI\") World Congress 2024, which included results from the SPRINGBOARD Phase\n \n 2b\...